Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Chief Medical Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 896,317 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 213,900 · Balance 896,317 F1: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 21:17 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 213,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-047036 · wk-form4_1783027029.xml · nonDerivative · entry 1 Zaki Mohamed · CIK 0002000697 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896,317 F1 · shares: Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:43 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 24,603 | $3.99 | $98,165.97 |
DisclosureSEC source: 0001628280-26-009282 · wk-form4_1771454620.xml · nonDerivative · entry 2 Zaki Mohamed · CIK 0002000697 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 682,417 F2 · shares: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:43 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 285,200 | $3.99 | $1,137,948.00 |
DisclosureSEC source: 0001628280-26-009282 · wk-form4_1771454620.xml · nonDerivative · entry 1 Zaki Mohamed · CIK 0002000697 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,020 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document |
| December 06, 2025 Filed Dec 9, 2025 22:09 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 41,068 | $3.29 | $135,113.72 |
DisclosureSEC source: 0001628280-25-056171 · wk-form4_1765318192.xml · nonDerivative · entry 1 Zaki Mohamed · CIK 0002000697 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,820 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:22 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 230,000 | $1.61 | $370,300.00 |
DisclosureSEC source: 0001628280-25-005862 · wk-form4_1739575362.xml · nonDerivative · entry 1 Zaki Mohamed · CIK 0002000697 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,888 F1 · shares: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 01:42 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 37,112 | $3.13 | $116,160.56 |
DisclosureSEC source: 0001628280-24-050543 · wk-form4_1733794961.xml · nonDerivative · entry 1 Zaki Mohamed · CIK 0002000697 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,888 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. F1 · acquired: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.